Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Engage Grants Program

University of Victoria

$25,000.00

Formulations for controlled release of glial derived neurotrophic factor (GDNF)

FY 2011-12

Summary
Glial cell-derived neurotrophic factor (GDNF), a protein that encourages the survival of neuronal cells, has been targeted as therapeutic for a variety of applications due to these properties. MedGenesis Therapeutix Inc., a Victoria based biopharmaceutical company, owns the commercial rights to manufacture the high quality version of GDNF necessary for conducting clinical trials using this therapeutic. In particular, they have chosen to study how GDNF can be used to treat both Parkinson's disease and chronic epilepsy using a variety of delivery methods. This project will initiate a first time collaboration between MedGenesis Therapeutix Inc. and the Willerth laboratory at the University of Victoria. Dr. Willerth is an expert in designing biomaterial scaffolds with specific properties to regulate the release of target proteins. This project will investigate different formulations of biomaterial scaffolds to determine how it affect the release rate of GDNF as an alternative method of delivering this protein for the treatment of the aforementioned diseases. Specifically, this project will investigate the use of an injectable mixture for localized delivery of GDNF over a variety of timescales.
Program
Engage Grants Program
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
418911-2011
Name nom
Willerth, Stephanie
Department département
Mechanical Engineering
Organization id
7
Institution établissement
University of Victoria
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2011
Competition year année de concours
2011
Award amount
25000
Program id
EGP
Program nane en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1554
Committee name en
Pacific Internal Decision Committee
Committee name fr
Comité de décision interne pour le Pacifique
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Partie
1
Nb partie
1
Application title
Formulations for controlled release of glial derived neurotrophic factor (GDNF)
Keyword
NSERC
Application summary
Glial cell-derived neurotrophic factor (GDNF), a protein that encourages the survival of neuronal cells, has been targeted as therapeutic for a variety of applications due to these properties. MedGenesis Therapeutix Inc., a Victoria based biopharmaceutical company, owns the commercial rights to manufacture the high quality version of GDNF necessary for conducting clinical trials using this therapeutic. In particular, they have chosen to study how GDNF can be used to treat both Parkinson's disease and chronic epilepsy using a variety of delivery methods. This project will initiate a first time collaboration between MedGenesis Therapeutix Inc. and the Willerth laboratory at the University of Victoria. Dr. Willerth is an expert in designing biomaterial scaffolds with specific properties to regulate the release of target proteins. This project will investigate different formulations of biomaterial scaffolds to determine how it affect the release rate of GDNF as an alternative method of delivering this protein for the treatment of the aforementioned diseases. Specifically, this project will investigate the use of an injectable mixture for localized delivery of GDNF over a variety of timescales.